Transfusion‑dependent
β‑thalassaemia (TDT)

People arranged in a double-helical formation on a field releasingblood bags into the air like balloons
FOR YOUR PATIENTS ≥12 YEARS OF AGE
WITH TRANSFUSION-DEPENDENT β‑THALASSAEMIA (TDT) WHO DO NOT HAVE A β0/ β0 GENOTYPE, FOR WHOM HAEMATOPOIETIC STEM CELL (HSC) TRANSPLANTATION IS APPROPRIATE, AND WHO DO NOT HAVE A HUMAN LEUKOCYTE ANTIGEN (HLA)-MATCHED RELATED DONOR1*

Help them let go of
chronic transfusions1

ZYNTEGLO (autologous CD34+ cells encoding βA-T87Q‑globin gene) is the first and only one-time gene therapy for transfusion‑dependent β‑thalassaemia that gives patients the potential to reach transfusion independence2

See how ZYNTEGLO works

▼Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App Store. Adverse events should also be reported to bluebird bio at safety.reporting@bluebirdbio.com, or by telephone to 0207 660 0754.

 
The majority of patients§ treated with ZYNTEGLO achieved transfusion independence1
No cases of lentiviral vector (LVV)-mediated insertional mutagenesis resulting in oncogenesis1
For TDT patients ≥12 years of age who do not have a β00 genotype and who do not have an HLA-matched related donor1

§Patients are eligible for assessment of transfusion independence if they have completed the parent study or achieved transfusion independence or will not achieve transfusion independence in the parent study.1

*INDICATION1

ZYNTEGLO is indicated for the treatment of patients 12 years and older with transfusion‑dependent β‑thalassaemia (TDT) who do not have a β00 genotype, for whom haematopoietic stem cell (HSC) transplantation is appropriate but an HLA-matched related HSC donor is not available.

ZYNTEGLO has been granted conditional authorisation. This means that there is more evidence to come about the medicine, which bluebird bio will provide. Every year, the European Medicines Agency will review any new information that becomes available.2